Compare iShares Bitcoin Trust (IBIT) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Eli Lilly And Co — how do they compare? iShares Bitcoin Trust trades at $46.99 (market cap $67.31B), while Eli Lilly And Co trades at $1,169.35 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 15.5× iShares Bitcoin Trust's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Eli Lilly And Co for 93 Days on average.
| IBIT | LLY | |
|---|---|---|
Market Cap | $67.31B | $1.04T |
Volume | 56,154,544 | 3,064,878 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $1.28K |
52-Week Low | $33.29 | $799.57 |
Typical Hold Time | 40 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal. The stock faces immediate support at $47 and resistance at $48. Recent news highlights significant institutional interest, with BlackRock's IBIT recording $196 million in daily inflows according to 24/7 Wall Street on October 4, 2026.
The outlook remains positive with strong institutional inflows and technical momentum, though the absence of traditional financial metrics requires careful evaluation. Key risks include market volatility and dependency on Bitcoin ETF performance, while analyst sentiment appears cautiously optimistic based on recent fund flow trends.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
